Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1231-1238

  Ligthart, S T ^a   Bidard, F C ^b   Decraene, C ^c   Bachelot, T ^d   Delaloge, S ^e   Brain, E ^b   Campone, M ^f   Viens, P ^g   Pierga, J Y ^b   Terstappen, L W M M ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b INSTITUT CURIE   (France)

^c INSTITUT CURIE   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Nantes St Herblain and Centre de Recherche en Cancérologie et Immunologie   (France)

^g INSTITUT PAOLI CALMETTES   (France)

Author keywords

Automated analysis; Breast cancer; Circulating tumor cells; Her 2; Quantitative assessment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ALGORITHM; ARTICLE; AUTOMATION; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FEASIBILITY STUDY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

BREAST NEOPLASMS; FEMALE; HUMANS; LEUKOCYTES; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84874667197     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds625     Document Type: Article

References (30)

1. Coussens L, Yangfeng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
3. Wolff AC, Hammond MEH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
4. Fabi A, Di Benedetto A, Metro G et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011; 17: 2055-2064.
5. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009; 20: 1499-1504.
6. Bidard FC PJ, Soria JC, Thiery JP. Translating metastasis-related biomarkers to the clinic, progress and pitfalls. Nat Rev Clin Oncol 2013; in press.
7. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
8. Liu MC, Shields PG, Warren RD et al. Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer. J Clin Oncol 2009; 27: 5153-5159.
9. Nakamura S, Yagata H, Ohno S et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010; 17: 199-204.
10. Nole F, Munzone E, Zorzino L et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008; 19: 891-897.
11. Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012; 23: 618-624.
12. Hayes DF, Walker TM, Singh B et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002; 21: 1111-1117.
13. Meng S, Tripathy D, Shete S et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 2006; 103: 17361-17365.
14. Meng SD, Tripathy D, Shete S et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101: 9393-9398.
15. Bidard FC, Mathiot C, Degeorges A et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010; 21: 1765-1771.
16. Coumans FAW, Doggen CJM, Attard G et al. All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010; 21: 1851-1857.
17. Kraan J, Sleijfer S, Strijbos MH et al. External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study. Cytometry B Clin Cytom 2010; 80B: 112-118.
18. Ignatiadis M, Rothe F, Chaboteaux C et al. HER2-positive circulating tumor cells in breast cancer. Plos One 2011; 10(6): e15624.
19. Riethdorf S, Muller V, Zhang LL et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16: 2634-2645.
20. Pierga JY, Petit T, Delozier T et al. Neoadjuvant bevacizumab, trastuzumab and chemotherapy for primary inflammatory HER-2positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol 2012; 13: 375-384.
21. Pierga JY, Bidard FC, Petit T et al. Monitoring Circulating Tumor Cells (CTC) and Circulating Endothelial Cells (CEC) during Neoadjuvant Combination of Trastuzumab and Bevacizumab with Chemotherapy in HER2 Overexpressing Inflammatory Breast Cancer (IBC): An Ancillary Study of BEVERLY 2 Multicenter Phase II Trial. San Antonio, TX: In San Antonio Breast Cancer Symposium, 2010, PD04-PD07.
22. Kagan M, Howard D, Bendele T et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Ligand Assay 2002; 25: 104-110.
23. Ligthart ST, Coumans FAW, Attard G et al. Automated classification of circulating tumor cells optimized using clinical outcome of castration resistant prostate cancer patients. PLos One 2011; 6: e27419.
24. Ligthart ST. Redefining Circulating Tumor Cells by image processing. Thesis, 2012 page 97-118.
25. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012; 30: 2601-2608.
26. Nadal R, Fernandez A, Sanchez-Rovira P et al. Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Res. 2012; 14(3): R71.
27. Punnoose EA, Atwal SK, Spoerke JM et al. Molecular biomarker analyses using circulating tumor cells. Plos One 2010.
28. Mayer JA, Pham T, Wong KL et al. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE (TM) platform. Cancer Genet 2011; 204: 589-595.
29. Hartkopf AD, Banys M, Fehm T. HER2-positive DTCs/CTCs in breast cancer. Recent Results Cancer Res 2012; 195: 203-1215.
30. Bidard FC, Fehm T, Ignatiadis M et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Met Rev 2013, November 6, [epub ahead of print], doi: 10.1007/s10555-012-9398-0.